Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Migaldendranib in healthy volunteers
NCT05105607Phase 1Completed
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dendranib in neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME) (4 arms). Primary endpoint: Number of Participants With Adverse Events. Started Jan 2022; status: completed.
02
Drugs
dendranib
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05105607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105607.